NASDAQ:SCYX - Scynexis Stock Price, Price Target & More

$1.32 +0.04 (+3.13 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$1.32
Today's Range$1.28 - $1.3450
52-Week Range$1.22 - $2.93
Volume199,434 shs
Average Volume374,419 shs
Market Capitalization$59.95 million
P/E Ratio-1.31
Dividend YieldN/A
Beta0.26

About Scynexis (NASDAQ:SCYX)

Scynexis logoSCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485

Debt

Debt-to-Equity Ratio0.48%
Current Ratio4.43%
Quick Ratio4.43%

Price-To-Earnings

Trailing P/E Ratio-1.31
Forward P/E Ratio-1.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales237.80
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book1.78

Profitability

EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-10,383.59%
Return on Equity-85.99%
Return on Assets-48.00%

Miscellaneous

Employees19
Outstanding Shares46,840,000

How to Become a New Pot Stock Millionaire

Scynexis (NASDAQ:SCYX) Frequently Asked Questions

What is Scynexis' stock symbol?

Scynexis trades on the NASDAQ under the ticker symbol "SCYX."

How were Scynexis' earnings last quarter?

Scynexis (NASDAQ:SCYX) released its earnings results on Tuesday, March, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter. The company had revenue of $0.06 million for the quarter. Scynexis had a negative return on equity of 85.99% and a negative net margin of 10,383.59%. View Scynexis' Earnings History.

What price target have analysts set for SCYX?

6 Wall Street analysts have issued 12-month price objectives for Scynexis' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Scynexis' share price to reach $8.25 in the next twelve months. View Analyst Ratings for Scynexis.

Who are some of Scynexis' key competitors?

Who are Scynexis' key executives?

Scynexis' management team includes the folowing people:
  • Dr. Marco Taglietti, Chief Exec. Officer, Pres and Director (Age 58)
  • Mr. Eric Francois, Chief Financial Officer (Age 43)
  • Mr. David Gonzalez Angulo M.D., Chief Medical Officer (Age 53)
  • Mr. Scott Sukenick J.D., Gen. Counsel
  • Dr. Rajeshwar Motheram Ph.D., VP of Pharmaceutical Devel.

Has Scynexis been receiving favorable news coverage?

News coverage about SCYX stock has been trending somewhat positive on Saturday, Accern reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Scynexis earned a news impact score of 0.14 on Accern's scale. They also assigned press coverage about the company an impact score of 46.12 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Scynexis?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Scynexis' stock price today?

One share of SCYX stock can currently be purchased for approximately $1.32.

How big of a company is Scynexis?

Scynexis has a market capitalization of $59.95 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Scynexis employs 19 workers across the globe.

How can I contact Scynexis?

Scynexis' mailing address is 101 HUDSON STREET SUITE 3610, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]


MarketBeat Community Rating for Scynexis (SCYX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  329
MarketBeat's community ratings are surveys of what our community members think about Scynexis and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Scynexis (NASDAQ:SCYX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Scynexis in the last 12 months. Their average twelve-month price target is $8.25, suggesting that the stock has a possible upside of 525.00%. The high price target for SCYX is $14.00 and the low price target for SCYX is $4.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.802.832.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.25$9.6667$9.50$11.00
Price Target Upside: 525.00% upside428.23% upside419.13% upside562.65% upside

Scynexis (NASDAQ:SCYX) Consensus Price Target History

Price Target History for Scynexis (NASDAQ:SCYX)

Scynexis (NASDAQ:SCYX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018Seaport Global SecuritiesInitiated CoverageBuy$4.00HighView Rating Details
10/24/2017GuggenheimInitiated CoverageBuy$6.00N/AView Rating Details
8/16/2017HC WainwrightSet Price TargetBuy$14.00HighView Rating Details
8/7/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
5/30/2017AegisReiterated RatingBuyMediumView Rating Details
5/9/2017Needham & Company LLCDowngradeBuy -> HoldHighView Rating Details
3/3/2017Royal Bank of CanadaReiterated RatingOutperform$15.00 -> $11.00N/AView Rating Details
10/7/2016WBB SecuritiesUpgradeBuy -> Strong-Buy$8.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Scynexis (NASDAQ:SCYX) Earnings History and Estimates Chart

Earnings by Quarter for Scynexis (NASDAQ:SCYX)

Scynexis (NASDAQ:SCYX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.22)($0.22)($0.22)
Q2 20181($0.17)($0.17)($0.17)
Q3 20181($0.21)($0.21)($0.21)
Q4 20181($0.25)($0.25)($0.25)

Scynexis (NASDAQ SCYX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018Q4 2017($0.27)$0.06 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.30)($0.27)$0.06 million$0.06 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.16)$0.06 million$0.06 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.37)($0.21)$0.06 millionViewN/AView Earnings Details
11/7/2016Q3 2016($0.38)($0.35)$0.10 million$0.06 millionViewN/AView Earnings Details
8/8/2016Q216($0.52)($0.56)$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.63)($0.52)$0.06 millionViewN/AView Earnings Details
11/13/2015Q315($0.62)($0.60)$0.06 millionViewN/AView Earnings Details
8/19/2015Q2 2015($0.53)$0.06 millionViewN/AView Earnings Details
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details
3/30/2015($0.71)($0.45)$5.30 millionViewN/AView Earnings Details
11/13/2014($0.53)($0.45)$4.38 millionViewN/AView Earnings Details
8/13/2014Q2 2014($2.12)$4.64 millionViewN/AView Earnings Details
6/16/2014Q1 2014($21.53)$4.71 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Scynexis (NASDAQ:SCYX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Scynexis (NASDAQ SCYX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 18.35%
Insider Trading History for Scynexis (NASDAQ:SCYX)
Institutional Ownership by Quarter for Scynexis (NASDAQ:SCYX)

Scynexis (NASDAQ SCYX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Gonzalez David AnguloInsiderBuy6,000$1.36$8,160.00101,790View SEC Filing  
3/8/2018David C HastingsDirectorBuy11,834$1.69$19,999.4631,834View SEC Filing  
3/8/2018Eric FrancoisCFOBuy5,917$1.69$9,999.7324,917View SEC Filing  
3/8/2018Gonzalez David AnguloInsiderBuy14,790$1.69$24,995.1088,790View SEC Filing  
3/8/2018Marco TagliettiCEOBuy100,000$1.69$169,000.00404,000View SEC Filing  
3/8/2018Scott SukenickGeneral CounselBuy2,959$1.69$5,000.712,959View SEC Filing  
9/22/2017Marco TagliettiCEOBuy10,000$2.23$22,300.00303,000View SEC Filing  
8/23/2017Marco TagliettiCEOBuy5,000$1.85$9,250.00287,007View SEC Filing  
8/15/2017Marco TagliettiCEOBuy10,000$1.61$16,100.00287,000View SEC Filing  
8/11/2017Gonzalez David AnguloInsiderBuy10,000$1.55$15,500.0072,000View SEC Filing  
6/21/2017David C HastingsDirectorBuy20,000$1.75$35,000.0020,000View SEC Filing  
5/12/2017Gonzalez David AnguloInsiderBuy15,000$1.70$25,500.0062,000View SEC Filing  
5/12/2017Marco TagliettiCEOBuy25,000$1.69$42,250.00277,000View SEC Filing  
12/21/2016Marco TagliettiCEOBuy25,000$3.30$82,500.00251,000View SEC Filing  
12/16/2016Gonzalez David AnguloInsiderBuy4,000$3.25$13,000.0046,000View SEC Filing  
9/15/2016Patrick MachadoDirectorBuy40,000$2.94$117,600.0060,000View SEC Filing  
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.008,850View SEC Filing  
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.0015,000View SEC Filing  
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.0040,000View SEC Filing  
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00225,000View SEC Filing  
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.004,225View SEC Filing  
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04124,754View SEC Filing  
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00119,000View SEC Filing  
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00110,500View SEC Filing  
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00106,000View SEC Filing  
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07100,000View SEC Filing  
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.0077,267View SEC Filing  
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.3652,267View SEC Filing  
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.0050,000View SEC Filing  
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Scynexis (NASDAQ SCYX) News Headlines

Source:
DateHeadline
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical ...Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical ...
www.prnewswire.com - April 20 at 5:25 PM
Generic Drugs Stocks Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXISGeneric Drugs Stocks' Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXIS
www.prnewswire.com - April 13 at 8:15 AM
Research Analysts Offer Predictions for Scynexis Q1 2018 Earnings (SCYX)Research Analysts Offer Predictions for Scynexis' Q1 2018 Earnings (SCYX)
www.americanbankingnews.com - April 12 at 7:09 AM
SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease ...SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease ...
www.prnewswire.com - April 10 at 5:33 PM
Scynexis (SCYX) Given Average Rating of "Buy" by AnalystsScynexis (SCYX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 10 at 9:13 AM
Scynexis (SCYX) Receives New Coverage from Analysts at Seaport Global SecuritiesScynexis (SCYX) Receives New Coverage from Analysts at Seaport Global Securities
www.americanbankingnews.com - April 10 at 8:30 AM
SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
finance.yahoo.com - April 10 at 8:19 AM
Scynexis (SCYX) Earns Buy Rating from Analysts at GuggenheimScynexis (SCYX) Earns Buy Rating from Analysts at Guggenheim
www.americanbankingnews.com - April 5 at 10:14 PM
Form 4 SCYNEXIS INC For: Apr 02 Filed by: Macdonald GuyForm 4 SCYNEXIS INC For: Apr 02 Filed by: Macdonald Guy
www.streetinsider.com - April 5 at 10:04 AM
Form 4 SCYNEXIS INC For: Mar 29 Filed by: Angulo Gonzalez DavidForm 4 SCYNEXIS INC For: Mar 29 Filed by: Angulo Gonzalez David
www.streetinsider.com - April 2 at 8:32 AM
SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference - PR Newswire (press release)SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:21 AM
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 - PR Newswire (press release)SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:42 AM
SCYNEXIS to Present at the 17th Annual Needham Healthcare ConferenceSCYNEXIS to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 8:42 AM
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
finance.yahoo.com - March 20 at 5:21 PM
SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company UpdateSCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
finance.yahoo.com - March 13 at 7:22 PM
Gonzalez David Angulo Buys 14,790 Shares of SCYNEXIS Inc (SCYX) StockGonzalez David Angulo Buys 14,790 Shares of SCYNEXIS Inc (SCYX) Stock
www.americanbankingnews.com - March 12 at 10:17 AM
SCYNEXIS Inc (SCYX) Director Buys $19,999.46 in StockSCYNEXIS Inc (SCYX) Director Buys $19,999.46 in Stock
www.americanbankingnews.com - March 12 at 10:17 AM
SCYNEXIS Inc (SCYX) CEO Buys $169,000.00 in StockSCYNEXIS Inc (SCYX) CEO Buys $169,000.00 in Stock
www.americanbankingnews.com - March 12 at 10:16 AM
SCYNEXIS to Present at the 30th Annual ROTH Conference - PR Newswire (press release)SCYNEXIS to Present at the 30th Annual ROTH Conference - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:13 AM
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants - PR Newswire (press release)SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:13 AM
Scynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants - StreetInsider.comScynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - March 7 at 8:13 AM
SCYNEXIS to Present at the 30th Annual ROTH ConferenceSCYNEXIS to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 7 at 8:13 AM
BRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And WarrantsBRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants
www.reuters.com - March 6 at 5:43 PM
Scynexis (SCYX) Prices $30M Public Offering of Common Stock, WarrantsScynexis (SCYX) Prices $30M Public Offering of Common Stock, Warrants
www.streetinsider.com - March 6 at 5:43 PM
SCYNEXIS Announces Launch of Public Offering of Common Stock and WarrantsSCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
finance.yahoo.com - March 5 at 5:52 PM
SCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from AnalystsSCYNEXIS Inc (SCYX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 28 at 7:42 PM
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of ... - PR Newswire (press release)SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of ... - PR Newswire (press release)
www.prnewswire.com - February 2 at 9:02 AM
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
finance.yahoo.com - February 1 at 9:16 AM
SCYNEXIS to Participate in the Cantor Antibiotics Summit - PR Newswire (press release)SCYNEXIS to Participate in the Cantor Antibiotics Summit - PR Newswire (press release)
www.prnewswire.com - January 12 at 11:15 AM
SCYNEXIS to Participate in the Cantor Antibiotics SummitSCYNEXIS to Participate in the Cantor Antibiotics Summit
finance.yahoo.com - January 12 at 11:15 AM
Celgene (CELG) & SCYNEXIS (SCYX) Critical SurveyCelgene (CELG) & SCYNEXIS (SCYX) Critical Survey
www.americanbankingnews.com - January 9 at 7:08 PM
SCYNEXIS Provides Corporate and SCY-078 Pipeline UpdateSCYNEXIS Provides Corporate and SCY-078 Pipeline Update
finance.yahoo.com - January 5 at 12:22 PM
Comparing SCYNEXIS (SCYX) & Tetraphase Pharmaceuticals (TTPH)Comparing SCYNEXIS (SCYX) & Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - December 27 at 3:54 PM
Financial Analysis: SCYNEXIS (SCYX) and Its CompetitorsFinancial Analysis: SCYNEXIS (SCYX) and Its Competitors
www.americanbankingnews.com - December 26 at 9:21 PM
Head to Head Review: SCYNEXIS (SCYX) versus Its PeersHead to Head Review: SCYNEXIS (SCYX) versus Its Peers
www.americanbankingnews.com - December 19 at 5:22 PM
Contrasting SCYNEXIS (SCYX) & Its RivalsContrasting SCYNEXIS (SCYX) & Its Rivals
www.americanbankingnews.com - December 19 at 11:24 AM
ETFs with exposure to SCYNEXIS, Inc. : December 18, 2017ETFs with exposure to SCYNEXIS, Inc. : December 18, 2017
finance.yahoo.com - December 19 at 11:18 AM
SCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from BrokeragesSCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 5:26 PM
Reviewing SCYNEXIS (SCYX) and Its PeersReviewing SCYNEXIS (SCYX) and Its Peers
www.americanbankingnews.com - December 13 at 9:18 PM
Contrasting SCYNEXIS (SCYX) and Teligent (TLGT)Contrasting SCYNEXIS (SCYX) and Teligent (TLGT)
www.americanbankingnews.com - December 11 at 1:36 PM
SCYNEXIS (SCYX) Rating Increased to Sell at ValuEngineSCYNEXIS (SCYX) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - December 9 at 11:26 AM
Scynexis: This Cash-Rich $2 Biotech Stock Is A Strong Buy Before 2018 - Seeking AlphaScynexis: This Cash-Rich $2 Biotech Stock Is A Strong Buy Before 2018 - Seeking Alpha
seekingalpha.com - December 2 at 8:04 AM
SCYNEXIS (SCYX) Downgraded to Hold at Zacks Investment ResearchSCYNEXIS (SCYX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 2 at 6:22 AM
SCYNEXIS to Participate in Upcoming Investor ConferencesSCYNEXIS to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 28 at 10:54 AM
SCYNEXIS, Inc. (SCYX) Upgraded to "Buy" by Zacks Investment ResearchSCYNEXIS, Inc. (SCYX) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 25 at 12:14 PM
SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare ConferenceSCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 23 at 9:20 AM
SCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from AnalystsSCYNEXIS, Inc. (SCYX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 20 at 5:44 PM
SCYNEXIS Appoints Scott Sukenick as General CounselSCYNEXIS Appoints Scott Sukenick as General Counsel
finance.yahoo.com - November 18 at 11:46 AM
ETFs with exposure to SCYNEXIS, Inc. : November 10, 2017ETFs with exposure to SCYNEXIS, Inc. : November 10, 2017
finance.yahoo.com - November 11 at 1:23 PM
SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company UpdateSCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - November 9 at 1:04 PM

SEC Filings

Scynexis (NASDAQ:SCYX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Scynexis (NASDAQ:SCYX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Scynexis (NASDAQ SCYX) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.